Form 4: IN8BIO CFO Patrick McCall Granted Stock Options as Retention Award
SEC Form 4 Filing
IN8BIO's Chief Financial Officer, Patrick McCall, received a retention award in the form of stock options to purchase 250,000 shares of common stock on September 4, 2024.
Summary
- Patrick McCall, the Chief Financial Officer of IN8BIO, Inc., was granted stock options to purchase 250,000 shares of common stock on September 4, 2024.
- The options serve as a retention award and have an exercise price of $0.47 per share.
- The options vest in installments: 25% on March 4, 2025, 25% on September 4, 2025, and 50% on March 4, 2026, contingent upon continued service.
- The options expire on September 4, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive's continued contribution to the company.
Positives
- The granting of stock options to the CFO suggests an effort to retain key personnel.
- The vesting schedule incentivizes continued service and commitment from the CFO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders and incentivize long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for CFOs in publicly traded biotech companies.
- The vesting schedule is typical, designed to retain the executive over a multi-year period.
- Comparable companies such as Kite Pharma (acquired by Gilead) and Juno Therapeutics (acquired by Celgene) have used similar stock option plans to incentivize their executives.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CFO to drive long-term value.
- Employees may see this as a sign of stability and investment in the leadership team.
Key Dates
| Date | Description |
|---|---|
| 09/04/2024 | Date of transaction: Grant of stock options to Patrick McCall. |
| 03/04/2025 | 25% of the stock options vest. |
| 09/04/2025 | 25% of the stock options vest. |
| 03/04/2026 | 50% of the stock options vest. |
| 09/04/2034 | Expiration date of the stock options. |
| 09/05/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.